Literature DB >> 26386726

Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Priya Samuel1, Ryan Charles Pink1, Daniel Paul Caley1,2, James Michael Stevenson Currie1, Susan Ann Brooks1, David Raul Francisco Carter3.   

Abstract

Ovarian cancers have a high mortality rate; this is in part due to resistance to the platinum-based compounds used in chemotherapy. In this paper, we assess the role of microRNA-31 in the development of chemoresistance to cisplatin. We used previous data from microarray experiments to identify potential microRNAs (miRNAs) involved in chemoresistance. The functional significance of these microRNAs was tested using miRNA mimics. We used RNA-seq to identify pathways and genes de-regulated in the resistant cell line and then determined their role using RNAi. Analysis of publically available datasets reveals the potential clinical significance. Our data show that miR-31 is increased, whilst potassium channel calcium activated large conductance subfamily M alpha, member 1 (KCNMA1), a subunit of calcium-regulated big potassium (BK) channels, is reduced in resistant ovarian cells. Over-expression of miR-31 increased resistance, as did knockdown of KCNMA1 or inhibition of BK channels. This suggests that these genes directly modulate cisplatin response. Our data also suggest that miR-31 represses KCNMA1 expression. Comparing the levels of miR-31 and KCNMA1 to cisplatin resistance in the NCI60 panel or chemoresistance in cohorts of ovarian cancer tumours reveals correlations that support a role for these genes in vitro and in vivo. Here we show that miR-31 and KCNMA1 are involved in mediating cisplatin resistance in ovarian cancer. Our data gives a new insight into the potential mechanisms to therapeutically target in cisplatin resistance common to ovarian cancer.

Entities:  

Keywords:  BK channel; Cisplatin resistance; KCNMA1; Ovarian cancer; miR-31; miRNA

Mesh:

Substances:

Year:  2015        PMID: 26386726     DOI: 10.1007/s13277-015-4081-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma.

Authors:  Tengfei Zhang; Qiming Wang; Dan Zhao; Yaling Cui; Bangrong Cao; Liping Guo; Shih Hsin Lu
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

4.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Authors:  Xi Liu; Lorenzo F Sempere; Haoxu Ouyang; Vincent A Memoli; Angeline S Andrew; Yue Luo; Eugene Demidenko; Murray Korc; Wei Shi; Meir Preis; Konstantin H Dragnev; Hua Li; James Direnzo; Mads Bak; Sarah J Freemantle; Sakari Kauppinen; Ethan Dmitrovsky
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

Review 5.  Cisplatin: from DNA damage to cancer chemotherapy.

Authors:  S M Cohen; S J Lippard
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

6.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

8.  Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells.

Authors:  Chao-Jie Wang; Johannes Stratmann; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Conserved BK channel-protein interactions reveal signals relevant to cell death and survival.

Authors:  Bernd Sokolowski; Sandra Orchard; Margaret Harvey; Settu Sridhar; Yoshihisa Sakai
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

View more
  27 in total

1.  MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line.

Authors:  Yankun Liu; Sugui Han; Yuhui Li; Yan Liu; Di Zhang; Yufeng Li; Jinghua Zhang
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

2.  Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity.

Authors:  Zhifa Zhang; Xiaofeng Dai; Xiao Chen; Jianying Zhang
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

Review 3.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

4.  LncRNA NRON negatively regulates cisplatin-induced cell apoptosis via downregulating miR-31 in esophageal squamous cell carcinomas.

Authors:  Bo Liu; Xu Li; Jinbao Xie; Zhi Feng; Nanlong Lin; Minjie Yu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-01-24       Impact factor: 2.416

Review 5.  Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.

Authors:  Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan
Journal:  Genes Dis       Date:  2020-12-01

6.  Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.

Authors:  Priya Samuel; Laura Ann Mulcahy; Fiona Furlong; Helen O McCarthy; Susan Ann Brooks; Muller Fabbri; Ryan Charles Pink; David Raul Francisco Carter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

Review 7.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

Review 8.  Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments.

Authors:  Damiano Cirri; Francesco Bartoli; Alessandro Pratesi; Emma Baglini; Elisabetta Barresi; Tiziano Marzo
Journal:  Biomedicines       Date:  2021-05-04

9.  Failure of Elevating Calcium Induces Oxidative Stress Tolerance and Imparts Cisplatin Resistance in Ovarian Cancer Cells.

Authors:  Liwei Ma; Hongjun Wang; Chunyan Wang; Jing Su; Qi Xie; Lu Xu; Yang Yu; Shibing Liu; Songyan Li; Ye Xu; Zhixin Li
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

10.  MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.

Authors:  Bo-Chuan Lin; Dong Huang; Chao-Qun Yu; Yong Mou; Yuan-Hang Liu; Da-Wei Zhang; Feng-Jun Shi
Journal:  Med Sci Monit       Date:  2016-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.